EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer

Tomonori Tanei, Shigeto Seno iD, Yoshiaki Sota iD, Takaaki Hatano, Yuri Kitahara, Kaori Abe, Nanae Masunaga iD, Masami Tsukabe, Tetsuhiro Yoshinami, Tomohiro Miyake, Masafumi Shimoda, Hideo Matsuda iD und 1 weitere

Cancers · 05.03.2024 · 16 (5) · 1062

DOI: 10.3390/cancers16051062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 05.03.2024. Verfasst von Tomonori Tanei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita 565-0871, Osaka, Japan. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Breast cancer tumors frequently have intratumoral heterogeneity (ITH). Tumors with high ITH cause therapeutic resistance and have human epidermal growth factor receptor 2 (HER2) heterogeneity in response to HER2-targeted therapies. This study aimed to investigate whether high HER2 heterogeneity levels were clinically related to a poor prognosis for HER2-targeted adjuvant therapy resistance in primary breast cancers.

Methods

This study included patients with primary breast cancer (n = 251) treated with adjuvant HER2-targeted therapies. HER2 heterogeneity was manifested by the shape of HER2 fluorescence in situ hybridization amplification (FISH) distributed histograms with the HER2 gene copy number within a tumor sample. Each tumor was classified into a biphasic grade graph (high heterogeneity [HH]) group or a monophasic grade graph (low heterogeneity [LH]) group based on heterogeneity. Both groups were evaluated for disease-free survival (DFS) and overall survival (OS) for a median of ten years of annual follow-up.

Results

Of 251 patients with HER2-positive breast cancer, 46 (18.3%) and 205 (81.7%) were classified into the HH and LH groups, respectively. The HH group had more distant metastases and a poorer prognosis than the LH group (DFS: p < 0.001 (HH:63% vs. LH:91% at 10 years) and for the OS: p = 0.012 (HH:78% vs. LH:95% at 10 years).

Conclusions

High HER2 heterogeneity is a poor prognostic factor in patients with HER2-positive breast cancer. A novel approach to heterogeneity, which is manifested by the shape of HER2 FISH distributions, might be clinically useful in the prognosis prediction of patients after HER2 adjuvant therapy.

Schlagwörter

Stichwörter der Autor:innen

HER2 gene expressionbreast carcinomabreast neoplasmsintratumoral heterogeneityprognosis

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita 565-0871, Osaka, Japan.
  • Department of Bioinformatic Engineering, Graduate School of Information Science and Technology, Osaka University, 1-5 Yamadaoka, Suita 565-0871, Osaka, Japan.

ORCID-Profile: Shigeto Seno, Yoshiaki Sota, Nanae Masunaga, Hideo Matsuda

Zitieren

APA

Tanei, T., Seno, S., Sota, Y., Hatano, T., Kitahara, Y., Abe, K., Masunaga, N., Tsukabe, M., Yoshinami, T., Miyake, T., Shimoda, M., Matsuda, H., & Shimazu, K. (2024). High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers, 16(5), 1062. https://doi.org/10.3390/cancers16051062

Vancouver

Tanei T, Seno S, Sota Y, Hatano T, Kitahara Y, Abe K, et al. High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers. 2024;16(5):1062. doi:10.3390/cancers16051062

BibTeX
@article{Tanei2024,
  author = {Tanei, Tomonori and Seno, Shigeto and Sota, Yoshiaki and Hatano, Takaaki and Kitahara, Yuri and Abe, Kaori and Masunaga, Nanae and Tsukabe, Masami and Yoshinami, Tetsuhiro and Miyake, Tomohiro and Shimoda, Masafumi and Matsuda, Hideo and Shimazu, Kenzo},
  title = {High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {1062},
  doi = {10.3390/cancers16051062}
}
Kostenlos starten →